Overview

Efficacy of TR 987, Beta-1,3-1,6-D-glucan, in the Treatment of Chronic Venous Insufficiency Ulcers

Status:
Active, not recruiting

Trial end date:
2021-04-01

Target enrollment:

Participant gender:

Summary

The safety and efficacy of beta glucan products, and specifically TR 987, in the treatment of chronic venous insufficiency ulcers has been established. This study is designed to determine the most efficient method of treatment.

Phase:

Phase 2

Details

Lead Sponsor:

SerenaGroup, Inc.

Collaborators:

TR Therapeutics
TR Therapeutics, Inc.